• Bayer’s Leaps unit led a Series A financing in crop-biologicals developer Robigo to speed US commercialization of engineered microbial biopesticides.
• Funding targets fungal diseases in soybeans, lettuce, berries; expansion planned to additional soil-borne pathogens in broadacre crops.
• Robigo estimates the addressable market at USD 10 billion; it is developing alternatives to costly chemical crop-protection products.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bayer AG published the original content used to generate this news brief via Business Wire (Ref. ID: 20260917086669) on September 17, 2026, and is solely responsible for the information contained therein.